88 related articles for article (PubMed ID: 2370301)
1. Modulation of tissue responsiveness to angiotensin-II in hyperprolactinemic subjects.
Arafah BM; Gordon NH; Salazar R; Douglas JG
J Clin Endocrinol Metab; 1990 Jul; 71(1):60-6. PubMed ID: 2370301
[TBL] [Abstract][Full Text] [Related]
2. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects.
Anderson PW; Malarkey WB; Salk J; Kletsky OA; Hsueh WA
J Clin Endocrinol Metab; 1989 Sep; 69(3):518-22. PubMed ID: 2503532
[TBL] [Abstract][Full Text] [Related]
3. Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.
Carey RM; Vaughan ED; Peach MJ; Ayers CR
J Clin Invest; 1978 Jan; 61(1):20-31. PubMed ID: 338631
[TBL] [Abstract][Full Text] [Related]
4. Lack of enhanced responsiveness of plasma 18-hydroxycorticosterone and aldosterone to adrenocorticotropin as well as to angiotensin-II during moderate sodium depletion in type II diabetic subjects with normoreninemia.
Kigoshi T; Iwasaki R; Kaneko M; Nakano S; Azukizawa S; Uchida K; Morimoto S
J Clin Endocrinol Metab; 1991 Jun; 72(6):1200-5. PubMed ID: 1851181
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic modulation of aldosterone responsiveness to angiotensin II with changes in sodium intake.
Gordon MB; Moore TJ; Dluhy RG; Williams GH
J Clin Endocrinol Metab; 1983 Feb; 56(2):340-5. PubMed ID: 6822640
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium balance and calcium channel-blocking drugs on plasma aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension.
Anderson GH; Howland T; Domschek R; Streeten DH
J Clin Endocrinol Metab; 1986 Nov; 63(5):1126-35. PubMed ID: 3760114
[TBL] [Abstract][Full Text] [Related]
7. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
8. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man.
Shoback DM; Williams GH; Hollenberg NK; Davies RO; Moore TJ; Dluhy RG
J Clin Endocrinol Metab; 1983 Oct; 57(4):764-70. PubMed ID: 6309884
[TBL] [Abstract][Full Text] [Related]
9. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects.
Schiebinger RJ; Chrousos GP; Cutler GB; Loriaux DL
J Clin Endocrinol Metab; 1986 Jan; 62(1):202-9. PubMed ID: 2999177
[TBL] [Abstract][Full Text] [Related]
10. Evidence for functionally distinct subpopulations of steroidogenic cells in the domestic turkey (Meleagris gallopavo) adrenal gland.
Kocsis JF; Lamm ET; McIlroy PJ; Scanes CG; Carsia RV
Gen Comp Endocrinol; 1995 Apr; 98(1):57-72. PubMed ID: 7781965
[TBL] [Abstract][Full Text] [Related]
11. Diminished aldosterone responses to angiotensin II and adrenocorticotropin in hypocalcemic subjects: restoration of responsiveness with normocalcemia.
Brickman AS; Trujillo AL; Gutin MS; Tuck ML
J Clin Endocrinol Metab; 1987 Feb; 64(2):297-303. PubMed ID: 3025245
[TBL] [Abstract][Full Text] [Related]
12. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.
Dluhy RG; Bavli SZ; Leung FK; Solomon HS; Moore TJ; Hollenberg NK; Williams GH
J Clin Invest; 1979 Nov; 64(5):1270-6. PubMed ID: 500810
[TBL] [Abstract][Full Text] [Related]
13. Activity of [des-aspartyl1]-angiotensin II in primary aldosteronism.
Carey RM; Ayers CR; Vaughan ED; Peach MJ; Herf SM
J Clin Invest; 1979 Apr; 63(4):718-26. PubMed ID: 438332
[TBL] [Abstract][Full Text] [Related]
14. Prolactin response to perphenazine. A sensitive and specific test for pituitary tumor in hyperprolactinemic women.
Mattox JH; Fortunato SJ
J Reprod Med; 1986 Dec; 31(12):1098-101. PubMed ID: 3795197
[TBL] [Abstract][Full Text] [Related]
15. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade.
Gordon MS; Williams GH; Hollenberg NK
Endocr Res; 1992; 18(2):115-31. PubMed ID: 1516563
[TBL] [Abstract][Full Text] [Related]
16. Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients.
Muratori M; Romano C; Gambino G; Faglia G
Horm Res; 1994; 42(6):257-61. PubMed ID: 7698720
[TBL] [Abstract][Full Text] [Related]
17. Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.
Hollenberg NK; Williams GH; Burger B; Ishikawa I; Adams DF
J Clin Invest; 1976 Jan; 57(1):39-46. PubMed ID: 1245602
[TBL] [Abstract][Full Text] [Related]
18. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
Serri O; Kuchel O; Buu NT; Somma M
J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
[TBL] [Abstract][Full Text] [Related]
20. Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.
Martin MC; Weiner RI; Monroe SE; Roberts JM; Licko V; Jaffe RB
J Clin Endocrinol Metab; 1984 Sep; 59(3):485-90. PubMed ID: 6746862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
